Clinical interest in FTY720 has however not centred on its postulated cardioprotective effects, but rather on its immunosuppressant effects, which led to the approval of a commercial form of the drug for use as an oral treatment for multiple sclerosis (MS).33,34 One of the proposed explanations for the mechanism by which FTY720 suppresses the autoimmune response associated with MS is by binding to S1P1 in the lymphoid tissue. Here, S1PR1 is linked to myeloid sarcoma.